Adhesin-enterotoxin chimera based immunongenic composition against enterotoxigenic
The inventive subject matter relates to an immunogenic composition composed of a chimeric molecule including a conformationally stable adhesin from Escherichia coli fused to a bacterial toxin A subunit, such as cholera toxin A subunit or heat-labile Escherichia coli toxin A subunit. The invention also relates to the adhesin-toxin chimera noncovalently associated with a toxin B subunit of the same or different species as the A subunit. The invention also relates to a method of utilizing an adhesin/toxin fusion composition to elicit an immune response.
1. An immunogenic composition comprising a purified fusion protein, the fusion protein containing an E. coli minor fimbrial adhesin polypeptide or monomer, wherein the fimbrial adhesin polypeptide or monomer is derived from Class 5 fimbriae or CS3 fimbriae and is operatively connected, directly or via a linker and donor strand polypeptide, to a toxin A subunit polypeptide.
2. The immunogenic composition of claim 1 , wherein the fimbrial adhesin polypeptide or monomer is operatively connected to the toxin A subunit polypeptide via a linker and donor strand polypeptide, wherein the fimbrial adhesin polypeptide or monomer is connected at its C-terminus to the linker, the linker is connected at its C-terminus to the donor strand, and the donor strand is connected at its C-terminus to the toxin A subunit.
3. The immunogenic composition of claim 1 , wherein the fusion protein is noncovalently linked to a toxin B subunit.
4. The immunogenic composition of claim 1 , wherein the toxin A subunit is selected from the group consisting of cholera toxin A; cholera toxin A2; E. coli heat-labile toxin A and E. coli heat-labile toxin A2.
5. The immunogenic composition of claim 1 , wherein the E. coli fimbrial adhesin polypeptide or monomer is selected from the group consisting of colonization factor antigen I; CS4; CS14; CS1; PCF071; CS17; CS19; CS2 and CS3.
6. The immunogenic composition of claim 5 , wherein the E. coli fimbrial adhesin polypeptide or monomer is selected from the group consisting of CfaE, CsfD, CsuD, CooD, CosD, CsdD, CsbD, CotD, and CstH.
7. The immunogenic composition of claim 1 , wherein the E. coli fimbrial adhesin polypeptide is a monomer or a polymer of adhesin polypeptides.
8. The immunogenic composition of claim 6 , wherein the E. coli fimbrial adhesin polypeptide or monomer has the sequence of SEQ ID NO: 4.
9. The immunogenic composition of claim 1 , wherein the linker has an amino acid sequence selected from the group consisting of SEQ ID No. 1; SEQ ID No. 2 and SEQ ID No. 3.
10. The immunogenic composition of claim 1 , wherein the donor strand has the amino acid sequence of SEQ ID No. 5.
11. The immunogenic composition of claim 1 , wherein the donor strand is an 8 to 20 amino acid polypeptide from E. coli fimbrial major subunit or adhesin monomer selected from the group consisting of CfaB; CsfA; CsuA1; CsuA2; CooA; CosA; CsbA; CsdA; CotA and CstH.
12. The immunogenic composition of claim 1 , wherein the fusion protein contains a histidine tag operatively linked to the C-terminus of the donor strand and to the N-terminus of the toxin A subunit polypeptide.
13. The immunogenic composition of claim 1 , wherein the fusion protein comprises a polypeptide having a sequence selected from the group consisting of SEQ ID No. 6; SEQ ID No. 7; SEQ ID No. 9; SEQ ID No. 10; SEQ ID No. 11; SEQ ID No. 12; SEQ ID No. 13; SEQ ID No. 15; SEQ ID No. 16 and SEQ ID No. 30.
14. The immunogenic composition of claim 1 , wherein the toxin A subunit has the sequence of SEQ ID No. 18 or SEQ ID No. 19.
15. The immunogenic composition of claim 3 , wherein the fusion protein or the toxin B subunit is operatively connected at its N-terminus to a signal sequence.
16. The immunogenic composition of claim 3 , wherein the toxin B subunit is cholera toxin B or E. coli heat-labile toxin B.
17. The immunogenic composition of claim 3 , wherein the fusion protein and the toxin B subunit are expressed from a single expression vector.
18. The immunogenic composition of claim 3 , wherein the toxin B subunit has a sequence selected from the group consisting of SEQ ID No. 20; SEQ ID No. 21; SEQ ID No. 22 and SEQ ID No. 23.
19. The immunogenic composition of claim 15 , wherein the signal sequence is the LTIIb toxin signal sequence of SEQ ID No. 24.
20. A method of inducing an immune response comprising the steps:
a) administering a priming dose of the composition of claim 1 ; and
b) administering boosting doses, with a first dose at least 1 week after the priming dose, with a unit dose range of 50 μg to 1 mg of the immunogenic composition in a buffered aqueous solution, wherein an immune response is elicited.
21. The method of claim 20 , wherein the fusion protein is noncovalently linked to a toxin B subunit.
22. The method of claim 20 , wherein the E. coli fimbrial adhesin polypeptide or monomer is selected from the group consisting of CfaE; CsfD; CsuD; CooD; CosD; CsdD; CsbD; CotD and CstH.
23. The method of claim 20 , wherein the fimbrial adhesin polypeptide or monomer is operatively connected to the toxin A subunit polypeptide via a linker and donor strand polypeptide, wherein the fimbrial adhesin polypeptide or monomer is connected at its C-terminus to the linker, the linker is connected at its C-terminus to the donor strand, and the donor strand is connected at its C-terminus to the toxin A subunit.
24. The method of claim 20 , wherein the E. coli fimbrial adhesin polypeptide is a monomer or a polymer of adhesin polypeptides.
25. The method of claim 20 , wherein the fusion protein comprises a polypeptide having a sequence selected from the group consisting of SEQ ID No. 6; SEQ ID No. 7; SEQ ID No. 9; SEQ ID No. 10; SEQ ID No. 11; SEQ ID No. 12; SEQ ID No. 13; SEQ ID No. 15; SEQ ID No. 16 and SEQ ID No. 30.
26. The method of claim 20 , wherein the toxin A subunit is selected from the group consisting of cholera toxin A; cholera toxin A2; E. coli heat-labile toxin A and E. coli heat-labile toxin A2.
27. The method of claim 20 , wherein the toxin A subunit has the sequence of SEQ ID No. 18 or SEQ ID No. 19.
28. The method of claim 20 , wherein the immune response inhibits enterotoxigenic E. coli fimbriae adherence to human cells.
29. The method of claim 20 , wherein the immune response reduces or prevents diarrhea in humans.
30. The method of claim 20 , wherein the composition is administered subcutaneously, transdermally, intramuscularly, orally, transcutaneously or nasally.
31. The method of claim 20 , wherein the fusion protein is produced by a DNA expression system in a live attenuated bacterial vector prior to administration.
32. The method of claim 21 , wherein the toxin B subunit has a sequence selected from the group consisting of SEQ ID No. 20; SEQ ID No. 21; SEQ ID No. 22and SEQ ID No. 23.
33. The method of claim 21 , wherein the composition is administered subcutaneously, transdermally, intramuscularly, orally, transcutaneously or nasally.
34. The method of claim 21 , wherein the fusion protein is produced by a DNA expression system in a live attenuated bacterial vector prior to administration.
35. The method of claim 21 , wherein the immune response inhibits enterotoxigenic E. coli fimbriae adherence to human cells.
36. The method of claim 21 , wherein the immune response reduces or prevents diarrhea in humans.
37. The method of claim 23 , wherein the donor strand is an 8 to 20 amino acid polypeptide from E. coli fimbrial major subunit or adhesin monomer selected from the group consisting of CfaB; CsfA; CsuA1; CsuA2; CooA; CosA; CsbA; CsdA; CotA and CstH.
38. The method of claim 30 , wherein the composition is administered orally by solution or enteric coated granule capsule.
39. The method of claim 30 , wherein the composition is administered transcutaneously by a dry patch.
40. The method of claim 31 , wherein the bacterial vector is derived from a bacterium selected from the group consisting of E. coli , member of the genus Shigella , member of the genus Camplylobacter , member of the genus Salmonella , and member of the genus Vibrio .
41. The method of claim 33 , wherein the composition is administered orally by solution or enteric coated granule capsule.
42. The method of claim 33 , wherein the composition is administered transcutaneously by a dry patch.
43. The method of claim 34 , wherein the bacterial vector is derived from a bacterium selected from the group consisting of E. coli , member of the genus Shigella , member of the genus Camplylobacter , member of the genus Salmonella , and member of the genus Vibrio.